Treatment options for chronic hepatitis B not responding to interferon. (Q53929287)

22 May 2018

review article

1 reference

title

Treatment options for chronic hepatitis B not responding to interferon. (English)

1 reference

22 May 2018

1 reference

Stephanos J Hadziyannis

series ordinal

1

1 reference

22 May 2018

publication date

1 June 2003

1 reference

22 May 2018

published in

Journal of Hepatology

1 reference

22 May 2018

volume

38

1 reference

22 May 2018

issue

6

1 reference

22 May 2018

page(s)

853-855

1 reference

22 May 2018

Hepatitis B e antigen-negative chronic hepatitis B.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

1 reference

7 January 2021

Management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Treatment of HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Interferon alfa for chronic hepatitis B infection: Increased efficacy of prolonged treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Serum HBV-DNA levels in inactive hepatitis B virus carriers.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Repeated courses of alpha-interferon for treatment of chronic hepatitis type B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

A preliminary trial of lamivudine for chronic hepatitis B infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

Lamivudine-interferon combination therapy for chronic hepatitis B: further support but no conclusive evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2803%2900156-9

7 January 2021

10.1016/S0168-8278(03)00156-9

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018